Top

Published in:

01-07-2015 | Preclinical study

Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients

Authors: Valerie Cui Yun Koh, Jeffrey Chun Tatt Lim, Aye Aye Thike, Poh Yian Cheok, Minn Minn Myint Thu, Veronique Kiak Mien Tan, Benita Kiat Tee Tan, Kong Wee Ong, Gay Hui Ho, Wai Jin Tan, Yongcheng Tan, Ahmed Syed Salahuddin, Inny Busmanis, Angela Pek Yoon Chong, Jabed Iqbal, Shyamala Thilagaratnam, Jill Su Lin Wong, Puay Hoon Tan

Published in: Breast Cancer Research and Treatment | Issue 2/2015

Abstract

Breast cancer is the most common malignancy in Singapore women. Ductal carcinoma in situ (DCIS) is the putative, non-obligate precursor of the majority of invasive breast cancers. The efficacy of the Singapore breast-screening pilot project in detecting early stage breast cancer led to the launch of a national breast-screening programme, BreastScreen Singapore (BSS), in January 2002. In this study, we compared clinicopathological and immunohistochemical characteristics, as well as clinical outcomes, between screen-detected and symptomatic DCIS. The study cohort comprised 1202 cases of DCIS diagnosed at Singapore General Hospital from 1994 to 2010. Comparison of clinicopathological parameters, immunohistochemical results of ER, PR, HER2, CK14, EGFR, and 34βE12, and clinical outcomes was carried out between the 2 groups. Amongst 1202 cases, 610 (50.7 %) were screen-detected and 592 (49.3 %) were symptomatic DCIS. Screen-detected cases were smaller in size (P < 0.001), of lower nuclear grade (P = 0.004), and more frequently expressed ER (P < 0.001). Luminal A phenotype was more frequently observed in screen-detected DCIS, while triple-negative and HER2 phenotypes were more common in symptomatic DCIS (P < 0.001). The basal-like phenotype was also more frequent in symptomatic DCIS (P = 0.041). Mean and median follow-up was 99.7 and 97.8 months, respectively, with a maximum follow-up of 246.0 months. More symptomatic patients developed invasive recurrences compared to screen-detected patients (P = 0.001). A trend for better disease-free survival was observed in screen-detected patients (P = 0.076). Patients who were screen-detected experienced better overall survival than those with symptomatic DCIS (P = 0.007). Our data indicate a more favourable outcome of screen-detected DCIS patients confirming the role of BSS in early identification of this curable disease.

Silverstein MJ (1998) Ductal carcinoma in situ of the breast. BMJ 317(7160):734–739PubMedCentralPubMedCrossRef

Frykberg ER, Bland KI (1994) Overview of the biology and management of ductal carcinoma in situ of the breast. Cancer 74(1 Suppl):350–361PubMedCrossRef

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2014). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. http://seer.cancer.gov/csr/1975_2012/. Accessed 5 April 2014

Jara-Lazaro AR, Thilagaratnam S, Tan PH (2010) Breast cancer in Singapore: some perspectives. Breast Cancer 17(1):23–28. doi:10.1007/s12282-009-0155-3 PubMedCrossRef

Jorgensen KJ, Keen JD, Gotzsche PC (2011) Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology 260(3):621–627. doi:10.1148/radiol.11110210 PubMedCrossRef

Welch HG, Woloshin S, Schwartz LM (2008) The sea of uncertainty surrounding ductal carcinoma in situ–the price of screening mammography. J Natl Cancer Inst 100(4):228–229. doi:10.1093/jnci/djn013 PubMedCrossRef

Coldman A, Phillips N (2013) Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program. CMAJ 185(10):E492–E498. doi:10.1503/cmaj.121791 PubMedCentralPubMedCrossRef

Kerlikowske K (2010) Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010(41):139–141. doi:10.1093/jncimonographs/lgq027 PubMedCrossRef

Duffy SW, Agbaje O, Tabar L, Vitak B, Bjurstam N, Bjorneld L, Myles JP, Warwick J (2005) Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res 7(6):258–265. doi:10.1186/bcr1354 PubMedCentralPubMedCrossRef

10.

Moss S (2005) Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. Breast Cancer Res 7(5):230–234. doi:10.1186/bcr1314 PubMedCentralPubMedCrossRef

11.

Paci E, Duffy S (2005) Overdiagnosis and overtreatment of breast cancer: overdiagnosis and overtreatment in service screening. Breast Cancer Res 7(6):266–270. doi:10.1186/bcr1339 PubMedCentralPubMedCrossRef

12.

Kopans DB, Smith RA, Duffy SW (2011) Mammographic screening and “overdiagnosis”. Radiology 260(3):616–620. doi:10.1148/radiol.11110716 PubMedCrossRef

13.

Yen MF, Tabar L, Vitak B, Smith RA, Chen HH, Duffy SW (2003) Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 39(12):1746–1754PubMedCrossRef

14.

Collins LC, Achacoso N, Haque R, Nekhlyudov L, Fletcher SW, Quesenberry CP Jr, Schnitt SJ, Habel LA (2013) Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat 139(2):453–460. doi:10.1007/s10549-013-2539-5 PubMedCentralPubMedCrossRef

15.

Donker M, Litiere S, Werutsky G, Julien JP, Fentiman IS, Agresti R, Rouanet P, de Lara CT, Bartelink H, Duez N, Rutgers EJ, Bijker N (2013) Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31(32):4054–4059. doi:10.1200/JCO.2013.49.5077 PubMedCrossRef

16.

Zhang X, Dai H, Liu B, Song F, Chen K (2015) Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis. Eur J Cancer Prev. doi:10.1097/CEJ.0000000000000131

17.

Lakhani SR, Ellias IO, Schnitt SJ, Tan PH, van de Vijver MJ (2012) WHO classification of tumours of the breast, 4th edn. IARC, Lyon

18.

Tan PH (2001) Pathology of ductal carcinoma in situ of the breast: a heterogeneous entity in need of greater understanding. Ann Acad Med Singap 30(6):671–676 quiz 677 PubMed

19.

Thike AA, Iqbal J, Cheok PY, Tse GM, Tan PH (2013) Ductal carcinoma in situ associated with triple negative invasive breast cancer: evidence for a precursor-product relationship. J Clin Pathol 66(8):665–670. doi:10.1136/jclinpath-2012-201428 PubMedCrossRef

20.

Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23(1):123–133. doi:10.1038/modpathol.2009.145 PubMedCrossRef

21.

Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168PubMed

22.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. doi:10.1200/JCO.2013.50.9984 PubMedCrossRef

23.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502. doi:10.1001/jama.295.21.2492 PubMedCrossRef

24.

Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, Tan B, Tan P, Wong NS, Tan PH (2010) Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 34(7):956–964. doi:10.1097/PAS.0b013e3181e02f45 PubMedCrossRef

25.

Health Promotion Board (2015) BreastScreen Singapore. http://www.hpb.gov.sg/HOPPortal/programmes-article/3324. Accessed 26 Jan 2015

26.

Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ (2001) Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19(8):2263–2271PubMed

27.

Kong I, Narod SA, Taylor C, Paszat L, Saskin R, Nofech-Moses S, Thiruchelvam D, Hanna W, Pignol JP, Sengupta S, Elavathil L, Jani PA, Done SJ, Metcalfe S, Rakovitch E (2014) Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. Curr Oncol 21(1):e96–e104. doi:10.3747/co.21.1604 PubMedCentralPubMedCrossRef

28.

Barnes NL, Dimopoulos N, Williams KE, Howe M, Bundred NJ (2014) The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast. Eur J Surg Oncol 40(3):249–254. doi:10.1016/j.ejso.2013.12.013 PubMedCrossRef

29.

Ma KK, Lau SS, Cheung PS (2013) Ductal carcinoma in situ in Chinese women undergoing opportunistic breast cancer screening. Surg Pract 18(1):8–14. doi:10.1111/1744-1633.12042 CrossRef

30.

Evans AJ, Pinder SE, Ellis IO, Wilson AR (2001) Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen 8(3):149–151PubMedCrossRef

31.

Kessar P, Perry N, Vinnicombe SJ, Hussain HK, Carpenter R, Wells CA (2002) How significant is detection of ductal carcinoma in situ in a breast screening programme? Clin Radiol 57(9):807–814PubMedCrossRef

32.

Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA (1995) Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76(7):1197–1200PubMedCrossRef

33.

Page DL, Dupont WD, Rogers LW, Landenberger M (1982) Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 49(4):751–758PubMedCrossRef

34.

Sanders ME, Schuyler PA, Dupont WD, Page DL (2005) The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 103(12):2481–2484. doi:10.1002/cncr.21069 PubMedCrossRef

35.

Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF (1978) Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 239(18):1863–1867PubMedCrossRef

36.

Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96(12):906–920PubMedCrossRef

37.

Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Harris JR, Smith BL (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24(7):1031–1036. doi:10.1200/JCO.2005.02.9975 PubMedCrossRef

38.

Silverstein MJ (2003) The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186(4):337–343PubMedCrossRef

39.

Sue GR, Chagpar AB (2015) Predictors of recurrence in patients diagnosed with ductal carcinoma in situ. Am Surg 81(1):48–51PubMed

40.

Evans A (2003) The diagnosis and management of pre-invasive breast disease: radiological diagnosis. Breast Cancer Res 5(5):250–253. doi:10.1186/bcr621 PubMedCentralPubMedCrossRef

41.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102(9):627–637. doi:10.1093/jnci/djq101 PubMedCentralPubMedCrossRef

42.

Provenzano E, Hopper JL, Giles GG, Marr G, Venter DJ, Armes JE (2003) Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 39(5):622–630PubMedCrossRef

43.

Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R (2004) High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS. Eur J Surg Oncol 30(3):243–247. doi:10.1016/j.ejso.2003.11.004 PubMedCrossRef

44.

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691. doi:10.1200/JCO.2009.24.9284 PubMedCrossRef

45.

Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL (2011) Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 104(1):120–127. doi:10.1038/sj.bjc.6606021 PubMedCentralPubMedCrossRef

46.

Zhou W, Jirstrom K, Johansson C, Amini RM, Blomqvist C, Agbaje O, Warnberg F (2010) Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer 10:653. doi:10.1186/1471-2407-10-653 PubMedCentralPubMedCrossRef

47.

Zhou W, Jirstrom K, Amini RM, Fjallskog ML, Sollie T, Lindman H, Sorlie T, Blomqvist C, Warnberg F (2013) Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer 13:512. doi:10.1186/1471-2407-13-512 PubMedCentralPubMedCrossRef

48.

Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC (2007) Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 38(2):197–204. doi:10.1016/j.humpath.2006.08.017 PubMedCrossRef

49.

Dabbs DJ, Chivukula M, Carter G, Bhargava R (2006) Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 19(11):1506–1511. doi:10.1038/modpathol.3800678 PubMed

50.

Sprague BL, McLaughlin V, Hampton JM, Newcomb PA, Trentham-Dietz A (2013) Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. Breast Cancer Res Treat 141(1):145–154. doi:10.1007/s10549-013-2670-3 PubMedCentralPubMedCrossRef

51.

Wong FY, Wang F, Chen JJ, Tan CH, Tan PH (2014) Outcomes of low-risk ductal carcinoma in situ in Southeast Asian women treated with breast conservation therapy. Int J Radiat Oncol Biol Phys 88(5):998–1003. doi:10.1016/j.ijrobp.2014.01.018 PubMedCrossRef

52.

Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH, Feig BW, Ames FC, Kuerer HM (2005) Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 200(4):516–526. doi:10.1016/j.jamcollsurg.2004.11.012 PubMedCrossRef

53.

Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM (2011) Ductal carcinoma-in situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 18(10):2873–2878. doi:10.1245/s10434-011-1707-2 PubMedCrossRef

54.

Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160(7):953–958PubMedCrossRef

55.

Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F (2013) Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol 44(12):2684–2689. doi:10.1016/j.humpath.2013.07.010 PubMedCrossRef

56.

Parikh RR, Haffty BG, Lannin D, Moran MS (2012) Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 82(1):7–13. doi:10.1016/j.ijrobp.2010.08.027 PubMedCrossRef

Title: Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients
Authors: Valerie Cui Yun Koh
Jeffrey Chun Tatt Lim
Aye Aye Thike
Poh Yian Cheok
Minn Minn Myint Thu
Veronique Kiak Mien Tan
Benita Kiat Tee Tan
Kong Wee Ong
Gay Hui Ho
Wai Jin Tan
Yongcheng Tan
Ahmed Syed Salahuddin
Inny Busmanis
Angela Pek Yoon Chong
Jabed Iqbal
Shyamala Thilagaratnam
Jill Su Lin Wong
Puay Hoon Tan
Publication date: 01-07-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3472-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers

Race-associated biological differences among Luminal A breast tumors

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9

Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing

Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach

Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer